IL-17, IL-23 and IL-12/23 biologics on every 2026 Guam Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 1 stand-alone Part D plans in Guam cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | AARP Medicare Rx Preferred from UHC$0.00/moS5820-035 |
|---|---|
| Stelaraustekinumab | Not covered |
| ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and others | Not covered |
| Wezlanaustekinumab-auub | Not covered |
| Selarsdiustekinumab-aekn | Not covered |
| Skyrizirisankizumab | Tier 5PA25%QL 1/28d |
| Tremfyaguselkumab | Tier 5PA25% |
| Cosentyxsecukinumab | Tier 5PA25%QL 10/30d |
| Taltzixekizumab | Not covered |
| Bimzelxbimekizumab | Not covered |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.